Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie zur Bewertung der Wirksamkeit von IDCT (intradiskale Zelltherapie) bei Probanden mit einstufiger, symptomatischer leichter bis mittelschwerer lumbaler degenerativer Bandscheibenerkrankung (IDCT)

14. Oktober 2026 aktualisiert von: DiscGenics, Inc.

Eine prospektive, randomisierte, doppelblinde, scheinkontrollierte, multizentrische Studie zur Bewertung der Sicherheit und Wirksamkeit von IDCT bei Probanden mit einstufiger, symptomatischer leichter bis mäßiger lumbaler Bandscheibendegeneration

This is a Phase III, randomized, double-blinded, Sham-controlled, multi-center study in subjects with single-level, symptomatic lumbar (L3- S1) intervertebral disc degeneration. The study will have a 52-week primary period followed by 52 week Follow-up Period (total of 104 weeks).

The study protocol will be approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC), and the study will be conducted in accordance with Good Clinical Practice (GCP). All subjects will provide written informed consent prior to Screening.

Approximately 162 subjects will be enrolled in the study. Up to 45 days prior to treatment, subjects will be screened for study inclusion, which includes obtaining baseline MRI and X-ray imaging. Imaging results for subjects initially eligible for study participation will be sent to a central imaging vendor for review and confirmation of eligibility, including the number of levels with degeneration. Subjects meeting all inclusion/exclusion criteria will be assigned to the corresponding treatment arm group and subsequently randomized to IDCT or Sham.

Randomization will occur approximately 7 to 14 days prior to the scheduled treatment administration date.

Overall, 162 subjects will be enrolled and randomized to IDCT or Sham in a 2:1 ratio.

  • IDCT (n=108)
  • Sham (n=54)

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Adult subjects with a diagnosis of single-level, mild to moderate, symptomatic lumbar (L3-S1) intervertebral disc degeneration that give consent and meet all the inclusion criteria and none of the exclusion criteria will be enrolled in this study. The disease, single-level disc will be known as the 'target disc' and will be either L3/L4, L4/L5, or L5/S1.

Studientyp

Interventionell

Einschreibung (Geschätzt)

162

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Vereinigte Staaten
    • Alabama
      • Birmingham, Alabama, Vereinigte Staaten, 35235
        • Rekrutierung
        • Alabama Clinical Therapeutics
        • Hauptermittler:
          • Brad 205-833-2228, MD
        • Kontakt:
    • Arizona
      • Phoenix, Arizona, Vereinigte Staaten, 85054
        • Rekrutierung
        • Mayo Clinic (AZ)
        • Hauptermittler:
          • John Freeman, MD
        • Kontakt:
      • Scottsdale, Arizona, Vereinigte Staaten, 85251
        • Rekrutierung
        • HonorHealth
        • Hauptermittler:
          • Luis Tumialan, MD
        • Kontakt:
    • Arkansas
      • Little Rock, Arkansas, Vereinigte Staaten, 72205
        • Rekrutierung
        • University of Arkansas for Medical Sciences
        • Kontakt:
        • Hauptermittler:
          • Erica Petersen, MD
    • California
      • San Diego, California, Vereinigte Staaten, 92111
        • Rekrutierung
        • Solaris Research Institute
        • Hauptermittler:
          • Krishnan Chakravarthy, MD
        • Kontakt:
      • Santa Monica, California, Vereinigte Staaten, 90403
        • Rekrutierung
        • Source Healthcare
        • Hauptermittler:
          • Timothy Davis, MD
        • Kontakt:
      • Thousand Oaks, California, Vereinigte Staaten, 91320
        • Rekrutierung
        • Pain Management and Injury Relief
        • Kontakt:
        • Hauptermittler:
          • Alexander Hersel, MD
    • District of Columbia
      • Washington D.C., District of Columbia, Vereinigte Staaten, 20006
        • Rekrutierung
        • International Spine, Pain and Performance Center
        • Hauptermittler:
          • Mehul Desai, MD
        • Kontakt:
    • Florida
      • Jacksonville, Florida, Vereinigte Staaten, 32224
        • Rekrutierung
        • Mayo Clinic (FL)
        • Kontakt:
        • Hauptermittler:
          • Wenchun Qu, MD
      • Miami, Florida, Vereinigte Staaten, 33136
        • Rekrutierung
        • University of Miami Health System
        • Kontakt:
        • Hauptermittler:
          • Barth Green, MD
      • Orlando, Florida, Vereinigte Staaten, 32832
      • St. Petersburg, Florida, Vereinigte Staaten, 33709
        • Rekrutierung
        • Vantage Clinical Trials
        • Hauptermittler:
          • Robert Guirguis, MD
        • Kontakt:
      • Tampa, Florida, Vereinigte Staaten, 33709
        • Rekrutierung
        • Vantage Clinical Trials
        • Hauptermittler:
          • Jorge Leal, MD
        • Kontakt:
    • Idaho
      • Boise, Idaho, Vereinigte Staaten, 83709
        • Beendet
        • Injury Care Family Care Research
      • Post Falls, Idaho, Vereinigte Staaten, 83854
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60612
        • Rekrutierung
        • Rush University Medical Center
        • Hauptermittler:
          • John O'Toole, MD
        • Kontakt:
    • Indiana
      • Carmel, Indiana, Vereinigte Staaten, 46032
        • Rekrutierung
        • Indiana Spine Group
        • Kontakt:
        • Hauptermittler:
          • Kevin Macadaeg, MD
    • Kentucky
      • Louisville, Kentucky, Vereinigte Staaten, 40202
        • Rekrutierung
        • Norton Leatherman Spine Center
        • Kontakt:
        • Hauptermittler:
          • Steven Glassman, MD
    • Louisiana
      • New Orleans, Louisiana, Vereinigte Staaten, 70121
        • Rekrutierung
        • Ochsner Health System
        • Hauptermittler:
          • Maged Guirguis, MD
        • Kontakt:
    • Minnesota
      • Rochester, Minnesota, Vereinigte Staaten, 55905
        • Rekrutierung
        • Mayo Clinic (MN)
        • Hauptermittler:
          • Ryan D'Souza, MD
        • Kontakt:
    • Missouri
      • St Louis, Missouri, Vereinigte Staaten, 63141
        • Rekrutierung
        • The Orthopedic Center of St. Louis
        • Kontakt:
        • Hauptermittler:
          • Matthew Gornet, MD
    • New York
      • New York, New York, Vereinigte Staaten, 10022
        • Rekrutierung
        • Weill Cornell Medicine for Comprehensive Spine Care
        • Kontakt:
        • Hauptermittler:
          • Prabhav Deo, MD
    • North Carolina
      • Wilmington, North Carolina, Vereinigte Staaten, 28403
        • Rekrutierung
        • Wake Research
        • Hauptermittler:
          • Jeremy Hoff, MD
        • Kontakt:
      • Winston-Salem, North Carolina, Vereinigte Staaten, 27103
        • Rekrutierung
        • Carolinas Pain Institute/ Center For Clinical Research
        • Hauptermittler:
          • Christopher Gilmore, MD
        • Kontakt:
    • Ohio
      • Cleveland, Ohio, Vereinigte Staaten, 10524
        • Rekrutierung
        • Cleveland Clinic
        • Kontakt:
        • Hauptermittler:
          • Jijun Xu, MD
    • Oregon
      • Eugene, Oregon, Vereinigte Staaten, 97404
        • Rekrutierung
        • Pacific Sports and Spine
        • Hauptermittler:
          • Gregory Moore, MD
        • Kontakt:
    • Pennsylvania
      • King of Prussia, Pennsylvania, Vereinigte Staaten, 19406
        • Rekrutierung
        • Main Line Spine
        • Hauptermittler:
          • Scott Davidoff, MD
        • Kontakt:
    • Tennessee
      • Memphis, Tennessee, Vereinigte Staaten, 38120
    • Texas
      • Austin, Texas, Vereinigte Staaten, 78745
        • Rekrutierung
        • Pain Specialists of America
        • Hauptermittler:
          • Genaro Gutierrez, MD
        • Kontakt:
    • Utah
      • Salt Lake City, Utah, Vereinigte Staaten, 84108
        • Rekrutierung
        • University of Utah
        • Hauptermittler:
          • Zachary McCormick, MD
        • Kontakt:
    • Virginia
      • Richmond, Virginia, Vereinigte Staaten, 23238
        • Rekrutierung
        • Virginia iSpine Physicians
        • Hauptermittler:
          • Michael DePalma, MD
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Has a diagnosis of mild to moderate, symptomatic, single-level degenerative disc disease (DDD) from L3-S1.

  2. Has a target disc that meets Modified Pfirrmann Grade 3-7, as determined by a central radiologist.

  3. Is ≥18 and ≤75 years of age, skeletally mature, and has a body mass index (BMI) ≥18 kg/m2 and ≤38 kg/m2 at Screening.

  4. Has been experiencing chronic low back pain for at least 6 months prior to Screening.

  5. Has had low back pain that is unresponsive to at least 3 months of conservative care (nonoperative treatment) to include at least one non-pharmacological intervention which may include physical therapy, acupuncture, chiropractic manipulation, massage, and at home medically supervised exercise program and two pharmacological interventions which may include NSAIDs, acetaminophen, duloxetine, and/or injectable therapy.

  6. Has pre-treatment low back pain score of 45 to 90 on VAS (Visual Analogue Scale) for low back pain at Screening and Day 1.

  7. Has pre-treatment ODI score of 35 to 90 at Screening and Day 1.

  8. Is willing to voluntarily sign the informed consent form and agrees to the release of previous medical history for purposes of this study (i.e., HIPAA authorization) at Screening.

  9. Is physically and mentally able to comply with the protocol, able to understand and complete the required forms, and willing and able to adhere to the requirements of the protocol in the opinion of the Investigator.

  10. Female-born subjects of childbearing potential must agree to and comply with using highly effective methods of birth control for the duration of the study (e.g., oral contraceptive, implant, injectable, indwelling intrauterine device, sexual abstinence, condoms, or a vasectomized partner).-

    Exclusion Criteria:

    Physical/ Medical History Exclusion Criteria

  11. Has low back pain that in the Investigator's opinion is predominately myofascial in nature.

  12. Has constant, unchanging low back pain that is not improved in any spinal position.

  13. Has radiculopathy resulting from nerve compression.

  14. Has non-radicular unilateral or bilateral leg pain with intensity greater than 50% of the intensity of the low-back pain, as measured by VAS.

  15. Leg pain that is of radicular origin, i.e., due to stimulation of nerve roots or dorsal root ganglion of a spinal nerve by compressive forces.

  16. Has frequent leg pain that extends below the knee.

  17. Has severe unilateral or bilateral osteoarthritis of the knee or hip.

  18. Severe spinal arthritis

  19. Has cauda equina syndrome.

  20. Has had previous lumbar spine surgery.

  21. Has had previous disc invasive treatment procedures (i.e., intradiscal electrothermal therapy, intradiscal radiofrequency thermocoagulation) or intradiscal injections (i.e., injection of corticosteroids, methylene blue, dextrose, or glucosamine and chondroitin sulfate) or diagnostic discography at L3-S1 within the 3 months prior to Screening.

  22. Subjects who have had basivertebral nerve ablation at L3-S1.

  23. Has clinical suspicion of facet pain as the primary pain generator.

  24. Has current infection at the planned procedure site, active systemic infection, or current or prior history of lumbar spinal infection (i.e., discitis, septic arthritis, epidural abscess).

  25. Has a history of fibromyalgia.

  26. Has tested positive for Hepatitis B virus (HBV), Hepatitis C virus (HCV), or Human Immunodeficiency Virus (HIV).

  27. Has presence of an active malignancy or tumor, or a prior history of malignancy within the last five years (except for basal cell carcinoma of the skin).

  28. Has presence or prior history of a spinal malignancy.

  29. Has significant systemic disease, such as unstable angina or autoimmune disease, such as rheumatoid arthritis. Has a history of congenital or acquired coagulopathy or thrombocytopenia.

31. Is currently taking anticoagulant, antiplatelet, or thrombolytic medications (except for aspirin or nonsteroidal anti-inflammatory drugs [NSAIDS]) and at the Investigator's medical discernment and discretion is unable to withhold medications for the time required per site standard or care, prior to the IDCT injection or is taking antineoplastic medications.

32. Is at higher risk for post-surgical infection (e.g., taking immunosuppressants), has a severe infection or a history of serious infection.

33. Has concomitant conditions requiring daily oral steroid usage for more than 30 days in the preceding 90 days before Screening.

34. Is taking opioids greater than 20 MME per day on an intermittent (as needed) basis OR is taking 20 MME or greater daily for more than 3 months prior to Screening

35. Has a history of unexplained, easy, or persistent bruising or bleeding, bleeding from the gums, or bleeding problems experienced in previous surgical procedures.

36. Has a history of hypersensitivity or anaphylactic reaction to bovine products, sodium hyaluronate/ hyaluronan/ hyaluronic acid, gentamicin, amphotericin b, dimethyl sulfoxide (DMSO), crustaceous/ shellfish, or porcine products.

37. Has an uncontrolled psychiatric condition or substance/alcohol abuse that would potentially interfere with the subject's participation in the study within 2 years prior to Screening in the opinion of the Investigator.

38. Has positive serum pregnancy test or nursing at time of Screening or has plans to become pregnant within the planned length of the study (2 years).

39. Has a body habitus that precludes adequate fluoroscopic visualization for the procedure or the procedure is physically impossible.

40. Has or requires an implantable electronic defibrillator, pacemaker, or has other contraindication to MRI scanning or cannot tolerate MRI scanning. Subjects who are expected to require a defibrillator or pacemaker, as determined by the Investigator should be excluded.

41. Has participated in another clinical study within the 6 months prior to Screening.

42. Has been a recipient or plans to be a recipient during trial participation of stem cell product to treat the lumbar spine.

43. Has participated in a prior IDCT clinical study.

44. Has pending litigation against a health care professional, except where required by the insurer as a condition of coverage.

45. A person who would not be available for the entire planned length of the trial.

46. Has active or pending worker's compensation claims. 47. In the Investigators opinion, the subject is not suitable for participation in the clinical trial.

Imaging Exclusion Criteria:

48. Three discs (L3-S1) that have a Modified Pfirrmann Grade 4-7.

49. Has evidence of prior lumbar vertebral body fracture at L3-S1.

50. Has scoliosis with curvature > 10 degrees.

51. Has congenital spinal irregularities such as segmentation.

52. Has an acute fracture of the spine at the time of enrollment in the study. Clinically compromised vertebral bodies within L3-S1 due to current or past trauma, e.g., sustained pathological fracture or multiple fractures of vertebrae.

53. Has evidence of dynamic instability on lumbar flexion extension per screening radiographs as indicated by >4.5 mm of translational motion at L3-S1; >15° of angular motion at L3/-L4; >20° of angular motion at L4-L/5; or >25° angular motion at L5/-S1.

54. Has Grade 2 or higher spondylolisthesis at L3-S1, as assessed by Meyerding classification.

55. Has lumbar spondylitis or other undifferentiated spondyloarthropathy.

56. Has Modic Type III Changes at L3-S1.

57. Has radiographic evidence or suspicion of a full thickness annular tear at L3-S1.

58. Has evidence of abnormal disc morphology defined as an extrusion or sequestration according to Fardon classification at L3- S1.

59. Has herniation > 3 mm in AP dimension that is associated with nerve root compression.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: IDCT (n=108); Intradiscal injection of IDCT in a single target disc

1 mL intradiscal injection of 9,000,000 cells/mL
Biologisch: IDCT (rebonuputemcel)

Single intradiscal injection of 1 mL of 9,000,000 cells/mL IDCT in a single target disc.
Schein-Komparator: Sham (n=54);

Needle insertion up to the annulus of a single target disc.
Sonstiges: Sham (No Treatment)

Single Sham needle insertion up to the annulus of a single target disc.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Visual Analogue Scale (VAS) for low back pain
Zeitfenster: Week 52

VAS is a sliding visual scale of 0 being "no pain" and 100 being "worst pain Imaginable' to assess changesfrom baseline in low back pain compared to Sham
Week 52
Oswestry Disability Index (ODI)
Zeitfenster: Week 52

ODI is a 10-item questionnaire used to measure functional disability in people with low back pain. It is a self-administered tool that assesses how back pain affects daily activities like walking, sleeping, and personal hygiene, with scores ranging from 0% (no disability) to 100% (maximum disability).
Week 52
Adverse Events
Zeitfenster: Day 1 to Week 52 in each treatment group.

Incidence of grade 2 (moderate) or greater AEs and SAEs
Day 1 to Week 52 in each treatment group.
Adverse events of special interest
Zeitfenster: Day 1 to Week 52 in each treatment group

Incidence of Adverse Events of Special Interest (AESI) to include any symptomatic injury of the target disc including annular tear, disc herniation/extrusion/prolapse as well as discitis.
Day 1 to Week 52 in each treatment group

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Visual Analogue Scale (VAS)
Zeitfenster: Week 4, 12 and 26, 78 and 104

VAS is a sliding visual scale of 0 being "no pain" and 100 being "worst pain Imaginable' to assess changes from baseline in low back pain
Week 4, 12 and 26, 78 and 104
Oswestry Disability Index (ODI)
Zeitfenster: Week 4, 12 and 26, 78 and 105

ODI is a 10-item questionnaire used to measure functional disability in people with low back pain. It is a self-administered tool that assesses how back pain affects daily activities like walking, sleeping, and personal hygiene, with scores ranging from 0% (no disability) to 100% (maximum disability).
Week 4, 12 and 26, 78 and 105
EQ-5D
Zeitfenster: Enrollment through Week 104

EQ-5D is a validated too consisting of a set of questions covering five dimensions, with each dimension having a different severity level.

  1. Mobility: Ranging from "no problems walking about" to "confined to bed". Self-care: Ranging from "no problems with self-care" to "unable to wash or dress myself".
  2. Usual activities: Ranging from "no problems doing my usual activities" to "unable to do my usual activities" (e.g., work, study, housework).
  3. Pain/discomfort: Ranging from "no pain or discomfort" to "extreme pain or discomfort".
  4. Anxiety/depression: Ranging from "not anxious or depressed" to "extremely anxious or depressed".
  5. Visual Analog Scale (EQ VAS): A scale (typically 0-100) where respondents mark their overall health from "worst imaginable" to "best imaginable".
Enrollment through Week 104
Disc Volume
Zeitfenster: Day 1 to Week 104

MRI assessment of Disc Volume though Week 104
Day 1 to Week 104
Pain Medication Use
Zeitfenster: Enrollment to Week 104

Concomitant pain medication use for low back pain related to the target disc
Enrollment to Week 104
Concomitant Therapy
Zeitfenster: Enrollment to Week 104

Concomitant medical therapy for low back pain (physical therapy, acupuncture, chiropractic manipulation, massage, and at-home, medically supervised exercise program etc.) use for low back pain
Enrollment to Week 104
Treatment Failure Rate
Zeitfenster: Enrollment to week 104

Treatment failure rate (defined as an invasive non-surgical or surgical intervention) directly related to the target disc.
Enrollment to week 104
Adverse Events
Zeitfenster: Enrollment to Week 104

The incidence of grade 2 (moderate) or greater AEs and SAEs
Enrollment to Week 104
Adverse Events of Special Interest (AESI)
Zeitfenster: Enrollment to Week 104

The incidence of Adverse Events of Special Interest (AESI) observed defined as any one of the followings symptomatic injury of the target disc including annular tear, disc, herniation/extrusion/prolapse or any case of discitis.
Enrollment to Week 104

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
MRI Based evaluations
Zeitfenster: Enrollment through Week 104

MRI Evaluation of the lumbar spine will be reported as an aggregate in one report to assess of disc height, Modified Pfirrmann grade, Modic changes, annular tears/fissures, endplate integrity, herniation, and any additional noteworthy observations at 12, 26, 52, 78, and 104.
Enrollment through Week 104
X-ray evaluation of the lumbar spine
Zeitfenster: Screening through Week 104

X-ray evaluation of flexion/extension will be assessed and measure in degrees of angles.
Screening through Week 104

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

DiscGenics, Inc.

Ermittler

  • Studienleiter: Lisa Flood, DiscGenics, Inc.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

23. Dezember 2025

Primärer Abschluss (Geschätzt)

24. November 2027

Studienabschluss (Geschätzt)

24. November 2028

Studienanmeldedaten

Zuerst eingereicht

17. November 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

20. November 2025

Zuerst gepostet (Tatsächlich)

28. November 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

15. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

14. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • DGX-A02

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren